Inês Martins, PhD, managing science editor —

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

Adelson Research Foundation Supports 3-Year Myeloma Funding Initiative

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in Multiple Myeloma Research (APMMR). The three-year program will support seven investigators conducting translational research in multiple myeloma at four leading U.S. academic institutions. “Our…

Janssen Submits New Application to EMA for Darzalex Combo

Janssen Pharmaceuticals recently submitted a Type 2 variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for Darzalex (daratumumab). The request includes Darzalex’s combined use with other therapies to advance treatment options for adult patients with multiple myeloma (MM) who are unfit…

Safety Concerns Lead to Partial Hold of 2 Tecentriq Trials in Myeloma, Lymphoma

Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at the request of the U.S. Food and Drug Administration (FDA). Unexplained deaths in trials of Keytruda-based combinations prompted the FDA to halt other studies of immune…

Multiple Myeloma Research Foundation Is Planning $15 Million Immunotherapy Initiative

The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the foundation asking immuno-oncology experts, pharmaceutical industry leaders, and government healthcare officials to identify areas of greatest need. The initiative itself will be divided into two phases: a…